BIO
Bio-Rad Laboratories Inc
Bio-Rad Laboratories Inc historical holders
total: 5
Longleaf Partners Bio-Rad Laboratories Inc transactions over time
- Total transactions:
- 6
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 2
- Held since:
- 2023 Q2
- Held for:
- 12 quarters
- Latest activity:
- 2026 Q2
Mason Hawkins has been an institutional investor in Bio-Rad Laboratories Inc (BIO) since 2023 Q2. According to 2026 Q2 report, Mason Hawkins doesn't hold any shares. The fund/company first acquired BIO in 2023 Q2, initially purchasing 171,987 shares. Since the initial investment, Longleaf Partners has made 5 more transactions in this position.
When did Mason Hawkins exit their BIO position?
Mason Hawkins no longer holds Bio-Rad Laboratories Inc (BIO). They sold off their entire position in 2026 Q2, closing out an investment that began in 2023 Q2.
When did Mason Hawkins first invest in BIO?
Mason Hawkins first invested in Bio-Rad Laboratories Inc (BIO) in 2023 Q2 at the reported quarter-end price of $379.12 per share, acquiring 171,987 shares in their initial purchase.
What is Mason Hawkins's average cost basis for BIO?
Based on historical transaction data, Mason Hawkins's estimated cost basis for Bio-Rad Laboratories Inc (BIO) is approximately $358.72 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $358.72
- Weighted AVG sell price:
- $282.29
BIO transactions history by Longleaf Partners
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
0
|
$278.75
|
|
-100% (-140,913)
|
-3.73%
|
|
2025 Q4
|
3.89%
|
140,913
|
$302.99
|
$42,695,230
|
-16.90% (-28,666)
|
-0.77%
|
|
2025 Q3
|
4.20%
|
169,579
|
$280.39
|
$47,548,256
|
-22.80% (-50,088)
|
-1.19%
|
|
2025 Q1
|
4.60%
|
219,667
|
$243.56
|
$53,502,095
|
+11.52% (+22,698)
|
+0.48%
|
|
2023 Q4
|
4.65%
|
196,969
|
$322.89
|
$63,599,320
|
+14.53% (+24,982)
|
+0.59%
|
|
2023 Q2
|
4.75%
|
171,987
|
$379.12
|
$65,203,711
|
new
|
+4.75%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.